Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
2008-003389-25Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in mantle cell lymphoma (MCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2008-003389-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003389-25.